X Close

Janssen UCL Medicinal Personalization

Home

Menu

Project Team

The interdisciplinary JUMP team brought together thought leaders that provided input in the development of the JUMP tools from clinical, industry, pathology, and organizational perspectives.

Project manager

Jane Kinghorn, UCL Translational Project Manager

Jane obtained her PhD in Molecular Toxicology from the University of Surrey and has more than 15 years experience within the pharmaceutical industry. She has applied various techniques from high content imaging, multiplexed immunoassays, Affymetric arrays and quantitative PCR to the field of biomarker discovery and validation, assessing in vivo models, human exvivo cell systems and clinical samples. Jane has extensive experience in project management up to first-time-in-man. At GlaxoSmithKline, Jane was responsible for coordinating gene expression and epigenetic biomarker studies for the Immunoinflammation therapeutic area. Her expertise is in the application of cell biology and molecular/genetic technniques to advance biomarkers in the areas of Neuroscience and Immunoinflammation.

Management lead and PI

Simcha Jong, Assistant Professor, Programme Director UCL Healthcare Management Initiative, UCL School of Management

Screen Shot 2013-11-08 at 14.02.23

Simcha’s research focuses on business development challenges involved in the commercialisation of disruptive biomedical innovations. He has expertise working with academic entrepreneurs, biotechnology companies and big pharma in the implementation of organizationally disruptive medical technologies such as cell therapy products and point of care diagnostics services in viral disease management in the clinical context of the NHS. Simcha’s research has been published in top management journals as well as prominent practitioner-oriented publications such as Nature Biotechnology.

 

Lead for tool design and development

Anna Gola, Research Associate in Management Science and Innovation

Anna_GolaAnna’s research centers on the fields of health economics and personalized medicine, examining the challenges involved in the development of economic models and commercialization strategies for health-related products and services. Anna joined UCL from Imperial College London where she obtained a PhD in Mathematics and Statistics from the Department of Epidemiology and Biostatistics.

 

Hepatitis C lead

William Rosenberg, UCL Peter Scheuer Chair of Liver Diseaselnstitute of Liver and Digestive Health, Division of Medicine, Faculty of Medical Sciences.

William has a long-standing interest in the immune response to hepatitis viruses. We have built upon knowledge of the interactions between host and viruses to develop vaccines for the prophylaxis and treatment of viral hepatitis. In addition we investigate biomarkers of liver fibrosis. Our work has led to the identification of a panel of markers that can determine the severity of liver fibrosis and prognosis. We are currently undertaking further research to identify new markers of liver fibrosis using metabonomics and proteomics. The Group also initiates and participates in clinical studies ranging from epidemiology to clinical trials of drugs and diagnostic tests.

 

Industry lead

André Capt, Director New Business, Janssen Diagnostics

André has been working since more than 20 years both in the diagnostic and the pharmaceutical industry. Since the mid nineties he has been involved in the launch of diagnostic tools that have enabled  the transformation of HIV care into chronic disease. As part of Janssen Diagnostics, his passion is about personalized medicine and its potential to improve outcomes for specific patients through targeted therapies.

 

Pathology lead

Deenan Pillay, UCL Professor of Virology

Screen Shot 2013-11-08 at 13.59.42Deenan is head of the Research Department of Infection and Honorary Consultant Virologist at University College London Hospital.  He is Director of the NIHR UCLH/UCL Comprehensive Biomedical Research Centre, and is also UCL Partners Programme Director for Infectious Diseases. His research focuses on the biological and clinical implications of HIV drug resistance, and the molecular epidemiology of HIV. In addition, he works on international studies of HIV treatment rollout, and is Director of one of the five WHO Specialist Reference Laboratories for HIV drug resistance.